As air quality continues to worsen, children, pregnant women, elderly people, and those suffering from chronic diseases, ...

BI Incorporated, a subsidiary of for-profit prison company GEO Group, will help ICE pinpoint the locations of immigrants.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

Asthma care continues to develop, particularly in how treatment and long-term management are approached. This article outlines current treatment and management recommendations for patients aged 12 and ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for another condition, the drugmaker said on Tuesday.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an eosinophilic phenotype, according to a press release from GSK.Depemokimab ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...